Clinical trials: Erythropoietin
- Condition Erythropoietin
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy
Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects
The primary purpose of this study is to compare the PK parameters of a single dose of a test tablet formulation of AKB-6548 relative to a single dose of the reference AKB-6548 tablet formulation, both treatments administered…
- Trial name
- NCT02412449
- Testing
- AKB-6548 tablet, reference formulation given in the fasted state, AKB-6548 tablet, test formulation given in the fasted state., AKB-6548 tablet, test formulation given in the fed state
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Healthy Subjects
Study on Single Administration and Dose Increment of Recombinant Human Serum Albumin/Erythrocyte Fusion Protein for Injection
The purpose of the study was to evaluate the safety of rHSA/EPO to healthy subjects and to investigate the pharmacokinetic characteristics of rHSA/EPO in healthy subjects, and to obtain preliminary pharmacokinetic parameters.
- Trial name
- NCT03786289
- Testing
- Recombinant human serum albumin/erythropoietin fusion protein, Recombinant erythropoietin injection (CHO cells)
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Tianjin SinoBiotech Ltd.
Healthy
PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).
Erythropoietin is a glycoprotein which stimulates red blood cell production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow.
- Trial name
- NCT07025681
- Testing
- Erythropoietin alfa
- Where
- Bangladesh
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Incepta Pharmaceuticals Ltd
Healthy Volunteers
Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548
The primary purpose of this study is to assess the single-dose bioavailability of AKB-6548 with ferrous sulfate relative to AKB-6548 in healthy volunteers.
- Trial name
- NCT02327546
- Testing
- AKB-6548, Ferrous Sulfate
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Renal Insufficiency, Chronic
To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects
The study investigates the pharmacokinetics (absorption, distribution, elimination) of molidustat after intake of a single 75 mg tablet in subjects with renal impairment requiring hemo- or peritoneal dialysis compared to age-and…
- Trial name
- NCT02312973
- Testing
- Molidustat(BAY85-3934)
- Where
- 2 sites in Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects
Study design: Phase I, first-in-human, randomized, double-blind, placebo-controlled, sequential dose escalation study of intravenously administered HM10760A in healthy adult Caucasian and Japanese subjects.
- Trial name
- EPO (NCT01030315)
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Anemia
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
Pharmacokinetic/Pharmacodynamic Study of 3 Epoetin Alfa Formulations in Single Subcutaneous Doses Administered to Healthy Volunteers SPONSOR Biosidus S.A.
- Trial name
- NCT03822884
- Testing
- Epoetin Alfa 40000 UNT/ML
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bio Sidus SA
Anemia, Chronic Kidney Disease
Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure, Cancer
- Trial name
- NCT00097747
- Testing
- peginesatide
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Affymax
Healthy
Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers
Open label and monocentric Phase I Clinical Trial, to Determine the Pharmacokinetics and Pharmacodynamics of Recombinant Human Erythropoietin for Subcutaneous Use in an Adult Male Population
- Trial name
- RUBI (NCT04954989)
- Testing
- Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU, Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU
- Where
- India
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Megalabs
Healthy
To Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers
This Phase I study is to compare pharmacokinetics, safety and pharmacodynamics of EPORON and EPREX after single subcutaneous administration.
- Trial name
- NCT02580006
- Testing
- EPORON, EPREX
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Healthy
PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.
The hypothesis of this trial is that the test drug (Eritromax ®) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ®) in healthy subjects following administration of single intravenous…
- Trial name
- NCT01685333
- Testing
- Epoetin Alfa
- Where
- Brazil
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Healthy
PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant
The hypothesis of this trial is that the test drug (Human Recombiant Epoetin - Blau) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ® - Janssen-Cilag) in healthy subjects following…
- Trial name
- NCT01685359
- Testing
- Epoetin Alfa
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Natural Blood and Blood Product Toxicity
A Randomized, Double-blinded, Active Controlled Crossover Clinical Trial to Investigate PK, PD and Safety of GBPD002
Erythropoietin (EPO) biosimilarity for GBPD002 (test candidate) and Eprex® (comparator) has been evaluated by comparing the pharmacokinetic (PK) and pharmacodynamic (PD) properties following subcutaneous injection in human…
- Trial name
- NCT05585658
- Testing
- Erythropoietin alpha
- Where
- 2 sites in Bangladesh
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Globe Biotech Limited
Healthy
A Study of HM10760A (Long-acting Erythropoietin (EPO)) in Healthy Korean Subjects
Study design: Randomized, double-blind, placebo-controlled, sequential dose escalation Six ascending dose cohorts are planned Primary Objective: To evaluate the safety profile of single escalating intravenous dose levels of…
- Trial name
- NCT01013064
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
PK and PD Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects
The hypothesis of this trial is that the test drug (Eritromax ®) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ®) in healthy subjects following administration of single intravenous…
- Trial name
- NCT01664195
- Testing
- Epoetin Alfa
- Where
- Brazil
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Pharmacokinetics and Pharmacodynamics in Healthy Volunteers
Pharmacokinetics, Pharmacodynamics, and Safety of NANOKINE Compared With Eprex 4000 U in Healthy Volunteers
This clinical trial aims to compare the pharmacokinetic (PK), pharmacodynamic (PD) parameters, and safety between Nanokine of Nanogen Pharmaceutical Joint Stock Company and Eprex® of Janssen Cilag Ltd on healthy male volunteers.
- Trial name
- NCT06919861
- Testing
- Erythropoietin alfa
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Healthy
PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects.
The hypothesis of this trial is that the test drug (Eritromax ®) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ®) in healthy subjects following administration of multiple intravenous…
- Trial name
- NCT01664221
- Testing
- Epoetin Alfa
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Renal Insufficiency, Chronic
Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.
The epoetin is a glycoprotein and endogenous hormone, which is primarily synthesized by specific epithelial cells lining the kidney peritubular capillaries, and regulates continuous formation of red blood cells.
- Trial name
- NCT03572647
- Testing
- Eritromax, Eprex
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Healthy Volunteer
To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin
This is a Dose-Block Randomized, Double-blind Placebo controlled, Open-label Active controlled, Dose-escalation Study to investigate the safety, tolerability, and Pharmacokinetics/Pharmacodynamics of GC1113 after Single…
- Trial name
- NCT01363934
- Testing
- GC1113, Darbepoetin alfa
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Chronic Kidney Failure, Anaemia
Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects
A study to see how a single subcutaneous dose of Epoetin beta (NeoRecormon®) in healthy Japanese compares with a single subcutaneous dose of Epoetin beta (NeoRecormon®) in Caucasian Male subjects.
- Trial name
- NCT01085552
- Testing
- Epoetin Beta
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- InCROM Europe Clinical Research